Xeris Biopharma Holdings, Inc. XERS
At closeNov 11, 2026, 4:00 PM EST
After hours · Nov 11, 4:00 PM ET
- YTD
- +110.45%
- 1 year
- +122.04%
- Market cap
- 3.02B
- Revenue (ttm)
- 368.26M
- Profit margin
- -1.76%
- EPS (ttm)
- -0.03
- Shares out
- 182.70M
- Forward P/E
- 50.83
- YTD return
- +110.45%
- 1-year return
- +122.04%
- Volume
- 3.79M
- Avg volume
- 2.72M
- Open
- 15.99
- Previous close
- 15.83
- Day's range
- 15.93 – 16.57
- 52-week range
- 5.25 – 16.57
- Beta
- 0.84
- Analysts
- Strong Buy
- Price target
- 17.29 (+4.6%)
- Earnings date
- Mar 1, 2027
5D +3.20 (+24.02%)
Key statistics
- Enterprise value
- 2.99B
- PEG ratio
- 0.00
- Price / sales
- 8.20
- Price / book
- 61.87
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 44.20%
- Free cash flow
- 51.11M
- Total cash
- 131.08M
- Total debt
- 226.07M
- Return on equity
- -27.11%
- Short % of float
- 5.08%
- 50-day average
- 9.92
- 200-day average
- 7.69
Analyst view
Consensus: strong buy
- Target (low)
- 12.00
- Target (mean)
- 17.29
- Target (high)
- 21.00
- Strong buy1
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate 0.07125.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | 0.06 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.03167 | 0.06 | +0.03 | +89.45% |
| Aug 6, 2026 | Jun 30, 2026 | 0.01214 | -0.18 | -0.19 | -1,582.70% |
| May 7, 2026 | Mar 31, 2026 | -0.00274 | 0.01 | +0.01 | +464.96% |
| Mar 2, 2026 | Dec 31, 2025 | 0.03 | 0.06 | +0.03 | +100.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.01 | 0.0035 | -0.01 | -65.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Barclays | main | Overweight | Overweight |
| Nov 6, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Nov 6, 2026 | Piper Sandler | reit | Neutral | Neutral |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 6, 2026 | Barclays | main | Overweight | Overweight |
| Sep 10, 2026 | Leerink Partners | main | Outperform | Outperform |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- xerispharma.com
News
Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? 
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18 
Xeris Biopharma Q3 Earnings Call Highlights 
Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21 - Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18 
Xeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High on Better-Than-Expected Earnings 
Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings
Your note
Sign in to keep a note on XERS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Stock Award(Grant) | Jun 3, 2026 | 150,693 |
| HECHT BETH P | Officer | Sale | Nov 1, 2026 | 1,086,130 |
| JOHNSON JOHN H. | Director | Sale | Dec 18, 2025 | 698,083 |
| KONG GARHENG | Director | Stock Award(Grant) | Jun 3, 2026 | 238,337 |
| MCCULLOCH KEVIN | President | Sale | Nov 1, 2026 | 1,609,210 |
| NGUYEN ANH TU | Officer | Stock Award(Grant) | Jan 29, 2026 | 431,534 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.95% | 14,525,539 | 239.96M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 4.27% | 7,804,758 | 128.93M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.02% | 7,340,229 | 121.26M | Jun 29, 2026 |
| State Street Corporation | 2.64% | 4,821,566 | 79.65M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.50% | 4,570,751 | 75.51M | Sep 29, 2026 |
| Nuveen, LLC | 2.27% | 4,141,888 | 68.42M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 5,193,656 | 85.80M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 4,417,108 | 72.97M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.09% | 1,986,461 | 32.82M | Jun 29, 2026 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 1.07% | 1,951,890 | 32.25M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02% | 1,872,201 | 30.93M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.87% | 1,595,993 | 26.37M | Sep 29, 2026 |